NIH Clinical Center Search the Studies: Study Number, Study Title

Protocol Details

Genetics of Obesity, Diabetes, and Heart Disease in African Diaspora Populations

This study is currently recruiting participants.

Summary | Eligibility | Citations | Contacts




Sponsoring Institute

National Human Genome Research Institute (NHGRI)

Recruitment Detail

Type: Enrolling by Invitation
Gender: Male & Female
Min Age: 18 Years
Max Age: 120 Years

Referral Letter Required


Population Exclusion(s)

American Indian or Alaskan Native;
Hispanic or Latino;
Native Hawaiian/Pacific Islander


Cardiometabolic Diseases;
Natural History

Recruitment Keyword(s)



Cardiovascular Disease

Investigational Drug(s)


Investigational Device(s)




Supporting Site

National Human Genome Research Institute


- African Americans have one of the highest rates of type 2 diabetes in the United States, and often have other medical problems related to obesity and cardiovascular disease. These conditions have various risk factors, including high blood sugar levels, high cholesterol levels, and insulin resistance. However, these risk factors have not been studied very closely in individuals with African ancestry, including Afro-Caribbean and sub-Saharan Africa migrant populations. Researchers are interested in conducting a genetic study on obesity, adult-onset diabetes, heart disease, and other common health conditions in individuals with African ancestry.


- To collect genetic and non-genetic information from individuals with African ancestry to study common health conditions related to obesity, adult-onset diabetes, and heart disease.


- Individuals at least 18 years of age who self-identify as African American, Afro-Caribbean, or migrants from sub Saharan Africa.


- Participants will undergo a physical examination and will provide a blood sample for study.

- Participants will also answer questions about personal and family medical history and current lifestyle behaviors.

- No treatment will be provided as part of this protocol.

--Back to Top--



Subjects will include unrelated persons who self-identify as white or African American, Afro-Caribbean or migrant from sub-Saharan Africa. Adults of African ancestry are prioritized for this study because of the paucity of genetics studies investigating the association of risk alleles contributing to the prevalence of T2D, CVD, obesity and other common conditions in this population. A small proportion of whites (less than 10%) will be included in this study, as they are in Dr. Sumner s ongoing projects; they will have the same clinical measurements obtained in the same laboratory to serve as a comparison group. This study only includes adults because these phenotypes are more commonly present in adults. In summary, inclusion criteria include:

-Persons who self-identify as either

--African American


--A migrant from sub-Saharan Africa


-Persons >= 18 years

-Participation in a protocol with Dr. Anne Sumner, NIDDK/NIH


Related individuals are excluded to avoid biases in our analyses due to genomic similarities between people who are related. No prisoners will be included in this study. Pregnant women are excluded from this study because pregnancy induces changes in metabolism that would interfere with the measurements and outcomes of the study. In summary, exclusion criteria include:

-Individuals related to participants


-Pregnant women

--Back to Top--


Not Provided

--Back to Top--


Principal Investigator

Referral Contact

For more information:

Charles N. Rotimi, M.D.
National Human Genome Research Institute (NHGRI)
National Institutes of Health
Building 12A
Room 4047
12 South Drive
Bethesda, Maryland 20892
(301) 451-2303

Amy R. Bentley
National Human Genome Research Institute (NHGRI)
National Institutes of Health
Building 12A
Room 4047
12 South Drive
Bethesda, Maryland 20892
(301) 594-9781

Office of Patient Recruitment
National Institutes of Health Clinical Center (CC)
Building 61, 10 Cloister Court
Bethesda, Maryland 20892
Toll Free: 1-800-411-1222
Local Phone: 301-451-4383
TTY: TTY Users Dial 7-1-1

Clinical Trials Number:


--Back to Top--